Eli Lilly shares jumped in premarket Tuesday after the company reported better-than-expected fourth quarter results and revised its 2024 forecast ahead of expectations, amid soaring demand for its ...

7:00am: Modest falls expected; Eli Lilly jumps on earnings beat Stock futures in New York edged lower on Tuesday as investors braced for another busy day of corporate news. In pre-market trading, f...

Shares of Eli Lilly and Co. LLY, +5.77% rallied toward a fifth-straight record close in premarket trading Tuesday, after the drug maker's fourth-quarter earnings beat expectations, helped by a 16% ...

Louise Chen, Cantor Fitzgerald, joins 'Fast Money' to talk Eli Lilly ahead of earnings.

Nowadays, the market sends mixed signals to virtually every investor attempting to participate today, squeezing out a few percentage points of gains from the stock movements. With the Federal Reser...

The U.S. Food and Drug Administration's website said some doses of Eli Lilly's diabetes drug Mounjaro are available only in limited quantities through early March 2024.

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Lilly (LLY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the qu...

A rival posted highly encouraging annual results for 2023. A great deal of its growth was due to a certain category of medications Eli Lilly also has in its product lineup.

I forecast GLP-1 drugs to become the largest-selling pharmaceutical class, with US sales of $150 billion in 2030. GLP-1 agonists have shown favorable cardiovascular outcomes and beneficial effects ...

Norway's giant wealth fund says Novo Nordisk and Eli Lilly could be on course to become the first health care companies to join the trillion-dollar club.

The S&P 500's (^GSPC) historic growth story over the past six months cannot and should not be missed by investors. Deciphering which stocks on the S&P 500 to pick for further growth can be daunting.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts oft...

Eli Lilly (LLY) concluded the recent trading session at $645, signifying a +0.9% move from its prior day's close.

Eli Lilly & Co (NYSE: LLY) is in the green this morning following a report that it's in talks with Germany to have its weight-loss drug be included in the country's public health coverage.

There's lucrative growth in the healthcare segment. The largest financial companies are no longer big banks.